Authors
Loading...
International survey reveals HCPs prefer daratumumab and dexamethasone as first-line therapy for AL amyloidosis, emphasizing clinical criteria for management.
Paolo Milani (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: